Literature DB >> 1692945

Celiprolol has no direct or indirect relaxing effects in isolated arteries and veins.

S T O'Rourke1, P M Vanhoutte.   

Abstract

Experiments were designed to study the potential mechanisms underlying the vasodilator effect of celiprolol. Rings of canine left circumflex coronary artery and rat mesenteric artery, with and without endothelium, were suspended in organ chambers for isometric tension recording. In both blood vessels, celiprolol (10(-9)-10(-4) M) failed to produce relaxation in rings with and without endothelium; these same tissues relaxed in an endothelium-dependent manner to acetylcholine (10(-6) M). All tissues relaxed completely in the presence of papaverine (10(-4) M). In the coronary artery, isoproterenol (10(-9)-10(-4) M) produced endothelium-independent relaxations which were inhibited in a competitive fashion by celiprolol (pA2 = 7.52 +/- 0.14; slope = 0.98, 95% confidence limits = 0.80-1.15). In other experiments, strips of canine saphenous veins were incubated with [3H]norepinephrine [( 3H]NE) and suspended for superfusion. Electrical stimulation (2 Hz, 4 V, 2 ms for 6 min) produced an increase in [3H]NE overflow. Isoproterenol (2 X 10(-6) M) augmented the evoked release of [3H]NE. Treatment of the strips with celiprolol (up to 5 X 10(-6) M) did not inhibit isoproterenol-induced facilitation of [3H]NE release. Thus, although celiprolol is a potent antagonist of postjunctional beta-adrenoceptors in the coronary artery, no evidence was obtained for a direct or indirect vasodilator effect of celiprolol on isolated blood vessels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692945     DOI: 10.1097/00005344-199005000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Do partial agonist beta-blockers have improved clinical utility?

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

Review 2.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

3.  Lack of importance of NO in beta-adrenoceptor-mediated relaxation of large epicardial canine coronary arteries.

Authors:  M L Béa; B Ghaleh; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

4.  Celiprolol exerts microvascular dilatation by activation of beta 2-adrenoceptors.

Authors:  S Dhein; S Titzer; M Wallstein; A Müller; R Gerwin; B Panzner; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

5.  Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man.

Authors:  C de Mey; K Beithaupt; D Palm; U Fuhr; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats.

Authors:  M Kähönen; H Mäkynen; P Arvola; I Pörsti
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

Review 7.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.